Dna X (SONM) Receivables (2018 - 2026)

Dna X's Receivables history runs 9 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• Quarterly Receivables fell 135.31% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 135.31% YoY) and the FY2024 annual result came in at $4.5 million, down 82.79% from the prior year.
• Receivables was -$4.0 million for Q1 2026 at Dna X, down from $16.0 million in the prior quarter.
• Across five years, Receivables topped out at $33.6 million in Q3 2023 and bottomed at -$4.0 million in Q1 2026.
• A 5-year average of $16.2 million and a median of $15.8 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables soared 321.31% — and 2026, when it slumped 135.31%.
• Dna X's Receivables stood at $24.8 million in 2022, then gained by 5.84% to $26.3 million in 2023, then slumped by 85.24% to $3.9 million in 2024, then jumped by 313.96% to $16.0 million in 2025, then sank by 124.87% to -$4.0 million in 2026.
• Business Quant data shows SONM's Receivables at -$4.0 million in Q1 2026, $16.0 million in Q3 2025, and $9.8 million in Q2 2025.